Australian biotech AdvanCell nabs $112M Series C for radiopharmaceuticalsnews2025-02-03T13:58:26+00:00February 3rd, 2025|Endpoints News|
Maze and Metsera biotech IPOs to begin trading Fridaynews2025-01-31T07:02:38+00:00January 31st, 2025|Endpoints News|
8VC, a tech and life sciences VC firm behind Altos Labs, eyes $1B fundnews2025-01-29T19:00:20+00:00January 29th, 2025|Endpoints News|
Atalanta gets $97M boost to take two siRNAs into clinic for rare neuro disordersnews2025-01-28T12:00:02+00:00January 28th, 2025|Endpoints News|
Versant’s fourth obesity biotech starts with $65M and a GIP antagonistnews2025-01-28T11:00:52+00:00January 28th, 2025|Endpoints News|
Obesity startup Found drives weight loss with low-cost generic drugs over GLP-1s, new study showsnews2025-01-27T19:44:17+00:00January 27th, 2025|Endpoints News|
Metsera outlines $250M IPO plans as obesity biotech competition risesnews2025-01-27T14:38:40+00:00January 27th, 2025|Endpoints News|
Maze looks to lead IPO queue with $113M Nasdaq debutnews2025-01-27T12:07:37+00:00January 27th, 2025|Endpoints News|
Swarm Oncology launches with T cell therapy technology to treat solid tumorsnews2025-01-27T00:00:05+00:00January 27th, 2025|Endpoints News|
With Sam Altman’s help, Retro Biosciences eyes $1B to extend lifespan by 10 yearsnews2025-01-24T20:24:35+00:00January 24th, 2025|Endpoints News|
